Adults in England aged 50 years or older who received the bivalent BA.1 mRNA booster vaccine during the 2022 autumn campaign had substantially lower risks for COVID-related hospitalisation and death ...

EL PASO, Texas (Border Report) – Two men are in police custody after an undercover drug buy ended in shots fired at law enforcement officers in Arizona. The shooting took place in the parking lot of a ...

Viking Therapeutics' leading candidate posted strong mid-stage data and is undergoing phase 3 studies. Though there are some risks, the stock could soar if it can pass the upcoming clinical and ...

HOUSTON — Three men were injured in what authorities describe as a drug-related shooting Thursday night in northwest Harris County. The Harris County Precinct 4 Constable’s Office said deputies ...

A new XCCommerce and SmartBrief study shows AI-driven deal-seeking behavior is evolving, putting pressure on retailers to deliver relevant, unified incentives. Consumers care more about getting a ...

The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the pharmaceutical company said Wednesday. About two weeks ago, the FDA sent Moderna a ...

Novo Nordisk received final approval for a higher dose of its Wegovy weight-loss shot from the European Commission. Approval of the higher 7.2 milligram dose of Wegovy means that doctors in the EU can ...

A drug deal gone wrong in Centralia left one person shot Friday after three juveniles allegedly attempted to rob the dealer. At approximately 8:39 p.m., officers responded to a reported shooting in ...

After the FDA’s decision to reject a review of Moderna’s mRNA-1010 flu shot, executives explain what Americans will miss out on as other nations embrace the technology. The rest of the world may get ...

The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday. The move is the latest sign that the FDA, under Health Secretary Robert F.

In summer 2025, the SARS-CoV-2 JN.1 sublineage became dominant with more resistant variants, such as XFG, LP.8.1, and NB.1.8.1. COVID-19 mRNA boosters were therefore updated for the 2025–2026 season ...